CPT code 62280 covers the injection or infusion of a neurolytic agent into the subarachnoid space to ablate specific spinal nerves and reduce severe pain, commonly used in advanced cancer pain involving the torso. This procedure is clinically significant because it provides a targeted option for refractory pain when other medical management has failed, and it can alter care trajectories for patients with limited prognoses.

Key payers included in this analysis are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context, typical service settings, and payer coverage considerations for CPT code 62280. The publication outlines benchmark considerations and common billing practices associated with the code, highlights policy-relevant elements that affect utilization and authorization, and summarizes clinical indications where neurolytic subarachnoid injections are most applicable.

What readers will learn: clinical purpose and typical sites of service for CPT code 62280, how major national payers approach coverage and prior authorization in general terms, and the procedural and policy factors that influence coding and billing for advanced pain interventions. Data not available in the input is noted where applicable.